Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.36 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29826297 | 0.87 | KMT2A (0.43) | FAAHFNTAFNTBKDM4EPKM | |
| SCHEMBL30740711 | 0.84 | PDE7B (0.40) | MAPTLMNA | |
| SCHEMBL29826285 | 0.80 | GPR119 (0.41) | FAAHKDM4EPKMMAPTTGFBR1 | |
| SCHEMBL29825853 | 0.79 | FAAH (0.47) | FAAHKDM4EPKMGPR119 | |
| SCHEMBL24792585 | 0.78 | KMT2A (0.42) | KDM4ETP53GPR119SMN1; SMN2 | |
| SCHEMBL30056362 | 0.78 | KMT2A (0.42) | KDM4ETP53GPR119SMN1; SMN2 | |
| SCHEMBL29826449 | 0.74 | KMT2A (0.52) | FNTAFNTBKDM4EPKMMAPT | |
| SCHEMBL22462821 | 0.71 | FAAH (0.49) | FAAHKDM4EPKMGPR119 | |
| SCHEMBL31160584 | 0.71 | GPR119 (0.46) | FAAHKDM4EPKMGPR119 | |
| SCHEMBL31160555 | 0.69 | GPR119 (0.52) | FAAHGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | CARMOT THERAPEUTICS INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4563199-A2 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2025-05-15 | — | — | US | disclosed |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-01 | — | — | US | disclosed |
| EP-4284795-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022165076-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154137-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | FAAH 322/4885FNTA 2050/4885FNTB 3903/4885 |
| US-20230089073-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | FAAH 322/4885FNTA 2050/4885FNTB 3903/4885 |
| US-20240252492-A1 | GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | FAAH 322/4885FNTA 2050/4885FNTB 3903/4885 |
| US-12459929-B2 | GPCR receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | GLP1R, GCGR, GIPR | FAAH 322/4885FNTA 2050/4885FNTB 3903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.